Cryopyrin-Associated Periodic Syndrome (CAPS) Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-2032) - DelveInsight | Key Companies - Zydus Cadila, Novartis, Inflazome, Aclaris, Mabpharm, Amgen, Regeneron

As per DelveInsight, the Cryopyrin-Associated Periodic Syndrome therapeutics market is anticipated to grow immensely in the coming years owing to the expected improvement in the diagnosis rate in upcoming years, improvement in treatment strategies, advances in Research and Development, readily uptake of current as well as emerging therapies with patient convenient ROA and increasing awareness about this disease.

DelveInsight's "Cryopyrin-Associated Periodic Syndrome (CAPS) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cryopyrin-Associated Periodic Syndrome Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Cryopyrin-Associated Periodic Syndrome market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Cryopyrin-Associated Periodic Syndrome (CAPS): An Overview
Cryopyrin-associated Periodic Syndromes (CAPS) is a rare group of auto-inflammatory as well as a known autosomal dominant disorder that is believed to be caused due to a mutation on the exon 3 of the NLRP3 gene, which codes for Cryopyrin protein.

CAPS comprises a group of three disorders, varying with their severity and the organs they tend to affect upon the onset, namely Neonatal Onset Multisystem Inflammatory Disease (NOMID), also called as Chronic Inflammatory Neurological Cutaneous Articular Syndrome (CINCA), Familial cold auto inflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS).

CAPS is rare, found in about one in 360,000 to 1,000,000 people. CAPS is suspected by the patient's history, as well as by symptoms and signs found by the physician on physical examination during a fever episode. Bloodwork may reveal high levels of inflammation during flares.

Cryopyrin-Associated Periodic Syndrome (CAPS) Market Key Facts
• In 2019, the overall market size of CAPS in the United States was around USD 35 million. Among the approved therapies in the United States, Rilonacept generated USD 14 million in 2019. Among the approved therapies, Canakinumab has the edge over other choices due to its patient-friendly dosing and treatment cycle (i.e., once every eight weeks dosing frequency).
• In 2019, the total number of prevalent cases of CAPS in the United States was 674, which is anticipated to increase by 2032.
• In the United States, the highest number of type-specific prevalent cases was recorded in 2019 for FCAS, i.e., 293 cases.
• According to Orphanet (2020), the whole spectrum of CAPS has a prevalence of 1/360,000 in France, CINCA being the less common form. Males and females are equally affected.
• FCAS has a higher prevalence in North America and this may be elucidated by the pattern of inheritance as well as diagnostic criteria and terminology applied in the United States vs. Europe. In contrast in Europe, only a few patients with FCAS are recognized, while suggestively more MWS patients are known.
• According to NHS England (2013), the prevalence of CAPS is thought to be ~ 1 in 1 million in the United Kingdom.

Cryopyrin-Associated Periodic Syndrome (CAPS) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Cryopyrin-Associated Periodic Syndrome market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Cryopyrin-Associated Periodic Syndrome market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Cryopyrin-Associated Periodic Syndrome Market will Grow by 2032:
https://www.delveinsight.com/report-store/cryopyrin-associated-periodic-syndromes-caps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Cryopyrin-Associated Periodic Syndrome (CAPS) Epidemiology
The epidemiology section covers detailed insights into the historical and current Cryopyrin-Associated Periodic Syndrome patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Cryopyrin-Associated Periodic Syndrome Epidemiology Segmented as -
• Type-specific Prevalent Cases of CAPS in the 7MM [2019-2032]
• Age-Specific Prevalent Cases of CAPS in the 7MM [2019-2032]
• Total Prevalent Cases of CAPS in the 7MM [2019-2032]
• Treated cases of CAPS in the 7MM [2019-2032]
• Total Diagnosed Prevalent Cases of CAPS in the 7MM [2019-2032]
• Severity-specific Prevalent Cases of CAPS in the 7MM [2019-2032]

Get Key Insights Into the Evolving Cryopyrin-Associated Periodic Syndrome Epidemiology Trends:
https://www.delveinsight.com/report-store/cryopyrin-associated-periodic-syndromes-caps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Cryopyrin-Associated Periodic Syndrome (CAPS) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cryopyrin-Associated Periodic Syndrome market or expected to be launched during the study period. The analysis covers Cryopyrin-Associated Periodic Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Cryopyrin-Associated Periodic Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/cryopyrin-associated-periodic-syndromes-caps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Cryopyrin-Associated Periodic Syndrome (CAPS) Therapeutics Market Assessment
Although there are some treatment options available for CAPS, there is still a major requirement to recognize the significant unmet need for effective treatment options for CAPS. To overcome this major unmet need, a few major pharma and biotech giants are working towards the development of a better treatment approach for CAPS patients. Currently, Zydus Cadila is leading the therapeutics market with its Cryoprin-Associated Periodic Syndrome drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Cryopyrin-Associated Periodic Syndrome Therapeutic Market Include:
• Zydus Cadila
• Novartis
• Inflazome
• Roche
• Aclaris Therapeutics
• Mabpharm
• Amgen
• Swedish Orphan Biovitrum
• Regeneron Pharmaceuticals
And Many Others

Cryopyrin-Associated Periodic Syndrome Emerging and Marketed Therapies Covered in the Report Include:
• ZYIL 1: Zydus Cadila
• DFV890: Novartis Pharmaceuticals
• Zunsemetinib : Aclaris Therapeutics
• IZD334: Inflazome
• Kineret (Anakinra): Amgen/ Swedish Orphan Biovitrum
• Arcalyst (Rilonacept): Regeneron Pharmaceuticals
And Many More

Learn More About the Emerging Therapies & Key Companies in the Cryopyrin-Associated Periodic Syndrome Therapeutics Market:
https://www.delveinsight.com/sample-request/cryopyrin-associated-periodic-syndromes-caps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cryopyrin-Associated Periodic Syndrome Competitive Intelligence Analysis
4. Cryopyrin-Associated Periodic Syndrome Market Overview at a Glance
5. Cryopyrin-Associated Periodic Syndrome Background and Overview
6. Cryopyrin-Associated Periodic Syndrome Patient Journey
7. Cryopyrin-Associated Periodic Syndrome Epidemiology and Patient Population
8. Cryopyrin-Associated Periodic Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Cryopyrin-Associated Periodic Syndrome Unmet Needs
10. Key Endpoints of Cryopyrin-Associated Periodic Syndrome Treatment
11. Cryopyrin-Associated Periodic Syndrome Marketed Products
12. Cryopyrin-Associated Periodic Syndrome Emerging Therapies
13. Cryopyrin-Associated Periodic Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Cryopyrin-Associated Periodic Syndrome Market Outlook (7 major markets)
16. Cryopyrin-Associated Periodic Syndrome Access and Reimbursement Overview
17. KOL Views on the Cryopyrin-Associated Periodic Syndrome Market.
18. Cryopyrin-Associated Periodic Syndrome Market Drivers
19. Cryopyrin-Associated Periodic Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/cryopyrin-associated-periodic-syndromes-caps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.